Objective To investigate the effect of non-invasive mechanical ventilation on inflammatory factors, blood gas indexes and lung function in patients with chronic obstructive pulmonary disease (COPD) complicated with type II respiratory failure.
Methods Totally 95 COPD patients complicated with type Ⅱrespiratory failure were randomly divided into observation group (n=48) and control group (n=47). The control group was treated with routine symptomatic treatment, while the observation group was treated with non-invasive mechanical ventilation on the basis of control group. After 2 weeks of treatment, the clinical efficacy, inflammatory factors C reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), blood gas indexesarterial oxygen saturation (SaO2), partial pressure of carbon dioxide p(CO2), partial pressure of oxygen p(O2) and pulmonary function of the two groups were compared.
Results The total effective rate was 91.67% in the observation group, which was significantly higher than 74.47% in the control group (P < 0.05). Compared with treatment before, the levels of CRP, IL-6 and TNF-α in both groups were significantly lower after treatment (P < 0.01), and those indexes in the observation group were significantly lower than the control group (P < 0.01). Compared with treatment before, p(O2) and SaO2 in both groups increased significantly, and p(CO2) decreased significantly after treatment (P < 0.05 or P < 0.01). After treatment, p(O2) and SaO2 in the observation group were significantly higher than those in the control group, while p(CO2) was significantly lower than those in the control group (P < 0.05). Compared with treatment before, FEV1%, FVC and PEF in both groups increased significantly after treatment (P < 0.05 or P < 0.01), and FEV1%, FVC and PEF in the observation group were significantly higher than those in the control group (P < 0.05 or P < 0.01).
Conclusion Non-invasive mechanical ventilation can inhibit inflammation, improve respiratory function and enhance therapeutic effect of COPD patients with type II respiratory failure.